NASDAQ:IOSP - Innospec Stock Price, Forecast & News

Innospec's stock was trading at $72.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IOSP stock has decreased by 8.2% and is now trading at $66.56. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innospec.

Innospec is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Innospec.

Innospec Inc. (NASDAQ:IOSP) posted its quarterly earnings data on Tuesday, February, 18th. The specialty chemicals company reported $1.47 EPS for the quarter, topping the consensus estimate of $1.38 by $0.09. The specialty chemicals company earned $390.70 million during the quarter, compared to the consensus estimate of $400.45 million. Innospec had a net margin of 7.41% and a return on equity of 14.69%. The company's revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.62 earnings per share. View Innospec's earnings history.

Innospec announced a Semi-Annual dividend on Tuesday, November 5th. Stockholders of record on Tuesday, November 19th will be given a dividend of $0.52 per share on Wednesday, November 27th. The ex-dividend date of this dividend is Monday, November 18th. This is an increase from Innospec's previous Semi-Annual dividend of $0.50. View Innospec's dividend history.

1 brokers have issued 12 month target prices for Innospec's stock. Their forecasts range from $95.00 to $95.00. On average, they expect Innospec's stock price to reach $95.00 in the next year. This suggests a possible upside of 42.7% from the stock's current price. View analysts' price targets for Innospec.

News coverage about IOSP stock has trended extremely negative this week, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innospec earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutInnospec.

Innospec saw a decrease in short interest in March. As of March 13th, there was short interest totaling 510,100 shares, a decrease of 14.0% from the February 27th total of 593,000 shares. Based on an average daily trading volume, of 157,000 shares, the days-to-cover ratio is currently 3.2 days. Currently, 2.1% of the company's shares are sold short. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Ecolab (ECL), Sherwin-Williams (SHW), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Albemarle (ALB), NewMarket (NEU), Balchem (BCPC), Ashland Global (ASH), W. R. Grace & Co (GRA), Quaker Chemical (KWR), Stepan (SCL), Sensient Technologies (SXT), PolyOne (POL) and HB Fuller (FUL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), Las Vegas Sands (LVS), Altria Group (MO), Exxon Mobil (XOM), NVIDIA (NVDA), Franklin Resources (BEN), Colgate-Palmolive (CL), Eastman Chemical (EMN), Emerson Electric (EMR) and Invesco (IVZ).

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.72%), State Street Corp (2.90%), Champlain Investment Partners LLC (2.71%), Royce & Associates LP (2.42%), Geode Capital Management LLC (1.47%) and Nuveen Asset Management LLC (1.39%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View institutional ownership trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Wilshire Securities Management Inc., NWQ Investment Management Company LLC, Bank of New York Mellon Corp, Royce & Associates LP, Westwood Holdings Group Inc., and SG Americas Securities LLC. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Philip Curran, and Philip John Boon. View insider buying and selling activity for Innospec.

IOSP stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, FMR LLC, James Investment Research Inc., Thrivent Financial for Lutherans, Great West Life Assurance Co. Can, Bank of Montreal Can, Citigroup Inc., and Mackay Shields LLC. View insider buying and selling activity for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $66.56.

Innospec has a market capitalization of $1.63 billion and generates $1.51 billion in revenue each year. Innospec employs 2,000 workers across the globe. View additional information about Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]